Introduction
Septic shock syndrome resulting from excessive host immune responses induced by infectious organisms is a leading cause of death in hospitalized patients. [1] [2] [3] Pathophysiological changes in sepsis involve the pathogen-induced uncontrolled release from immune cells, particularly monocytes and macrophages, of pro-inflammatory mediators. 4 Gram-negative bacterial infection is one of the major causes of systemic bacterial sepsis. 5 Lipopolysaccharide (LPS), a constituent of the Gram-negative outer membrane, is the leading cause of sepsis. LPS induces a rapid increase of pro-inflammatory mediators, leading to lethal systemic tissue damage and multiple organ failure, which mimics the inflammatory responses of septic syndrome. 6 In mammals, membrane-bound CD14 and toll-like receptor 4 (TLR4)-MD-2 participate in cellular recognition of LPS. 7 Binding of LPS to TLR4 triggers the activation of members of the mitogen-activated protein kinase (MAPK) pathway including p38, p42/p44 extra-cellular signal-regulated kinase (ERK1/2), and c-Jun N-terminal kinase (JNK). 8 In resting un-stimulated cells, nuclear factor-κB (NF-κB), a heterodimeric complex composed of 50-and 65-kDa (p50/p65) protein subunits, 9 retains as an inactive complex bound to inhibitory κBα (IκBα) in the cytoplasm. While the cells are under pro-inflammatory stimulation by LPS, phosphorylation and degradation of IκBα permit NF-κB nuclear translocation and promote the expression of inflammatory genes including inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), and others. For personal use at PENN STATE UNIVERSITY on February 21, 2013 . bloodjournal.hematologylibrary.org From via the alteration of thrombin substrate specificity. TMD2-thrombin complex sequentially activates anti-coagulant protein C inactivating pro-coagulant cofactors Va and VIIIa. 11 TM expression also occurs in keratinocytes, 12 polymorphonuclear neutrophils (PMNs), 13 monocytes, 14 and endothelial cells, 15 indicating additional functions of TM besides anticoagulation. 16 Indeed TM domains function as an adhesion molecule, 17 an angiogenic factor, 18 and an anti-inflammatory agent through protein C dependent and independent mechanisms. 16, 19 Recently, anti-inflammatory activity of TM domain 1 (TMD1) was implied by observing that mice with a deleted TM lectin-like domain (TM LeD/LeD ) become more sensitive to LPS challenge through the suppressed expression of adhesion molecules via NFκB and MAPK signaling pathways. 20 Moreover, mice with a mutation in the TM gene (TM pro/pro ) strongly reduce the capacity to generate activated protein C, an anti-inflammatory agent in treatment of sepsis. 21 Mice harboring the latter mutation display an unchanged pulmonary immune response induced by respiratory pathogens and LPS, suggesting the importance of TMD1 in bacteria and LPS-induced inflammatory responses. 22 Furthermore, TMD1 sequesters high-mobility group-B1 (HMGB1) protein, a late cytokine mediator of lethal endotoxemia and sepsis, by interfering the binding of HMGB1 to receptor for the advanced glycation end product. 23 TMD1 also interferes with complement activation and protects against arthritis. 24 Presently, we have demonstrated that recombinant TMD1 (rTMD1) binds to LPS, which induces agglutination and enhances bacteria phagocytosis by macrophages. Moreover, rTMD1 has an anti-inflammatory role in the early phase of systemic inflammation in Gram- 
Materials and Methods

Preparation of recombinant TM domain (rTMD) proteins using both Pichia and mammalian protein expression systems
The pPICZαA and pCR3-EK vectors (Invitrogen, San Diego, CA) were used for expression and secretion of human rTMD proteins containing 6×His tag and c-Myc epitope for purification and for protein detection in Pichia pastoris and human embryonic kidney 293 mammalian protein expression systems. An enterokinase cutting site between the rTMD sequence and His/c-Myc tag allowed subsequent removal of the tag sequence. The purified rTMD proteins were examined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting. A non-tagged rTMD1 was prepared by incubation of rTMD1 with enterokinase. Further details are provided in Document S1 (available on the Blood website; see the Supplemental Materials link at the top of the online article).
Cells and cell culture
Human leukemia monocytic THP-1 cells and the murine macrophage cell line RAW 264.7
were obtained from Bioresource Collection and Research Center (BCRC, Hsinchu, Taiwan).
BCRC's recommendations of cell culture conditions were followed. For differentiation, THP-1 cells were plated in medium containing 10 nM phorbol 12-myristate 13-acetate (SigmaAldrich, St. Louis, MO) and allowed to adhere for 18 hours.
Inflammatory mediator assays
TNF-α in conditioned medium or mouse serum was measured by an enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN). Accumulation of nitrite in the medium or mouse serum was determined by a colorimetric assay using Griess reagent Green fluorescence data from 10,000 events (cells) per condition collected at 530 nm on a log scale were analyzed with CellQuest™ software (Becton Dickinson). 27 only.
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rTMD1 ligand analysis
Interaction of biotin-polyacrylamide (biotin-PAA)-sugars (GlycoTech, Rockville, MA) and rTMD1 was assayed on a PerkinElmer Envision instrument using the AlphaScreen program. 28 Details are provided in Document S1.
Analysis of Lewis antigens in E. coli LPS O111:B4
E. coli O111:B4 LPS (5 μg/well) was coated and blocked as described above. Antibodies ( 
Statistical analyses
Survival data were analyzed by log-rank test. Data expressed as the mean ± standard deviation (SD). Statistical significance was analyzed by unpaired Student's t test. Differences between more than two groups were compared by one-way analysis of variance or two-way analysis of variance and following Bonferroni's post hoc test, with P < 0.05 considered statistically significant.
only.
Results
rTMD1 treatment reduces LPS-induced inflammatory mediator production in macrophages
To test whether TMD1 has anti-inflammatory property, we prepared rTMD proteins using both Pichia pastoris and mammalian protein expression systems. The rTMD1 proteins obtained from both systems had similar molecular mass with glycosylation modification, which was about 35 kDa and as assayed by silver staining and Western blotting ( Figure S1A were used to test the interaction. In the absence of rTMD1, LPS dose-dependently increased TNF-α production ( Figure 1C ) and rTMD1 dose-dependently inhibited LPS-induced TNF-α production ( Figure 1C ), which are consistent with the hypothesis that LPS-rTMD1 binding results in the reduction effect of rTMD1 on the inflammatory mediator production by the cells .
rTMD1 blocks the LPS-induced signaling pathways
Phosphorylation and degradation of IκBα occurred in RAW 264.7 cells stimulated with LPS (100 ng/mL). The effect was totally reversed by rTMD1 (50 μg/mL, equals 2.18 nmole/mL) ( Figure 1D ). The LPS-induced nuclear translocation of NF-κB was also inhibited in a doseonly.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From dependent fashion by rTMD1 ( Figure 1E ). LPS-induced phosphorylation of ERK1/2 and p38 was also inhibited by rTMD1 ( Figure 1F ). Similar effects of rTMD1 on activation of signal transduction pathway were observed in THP-1 cells (data not shown). iNOS induction in the RAW 264.7 cells by LPS was also inhibited by rTMD1 ( Figure 1G ). suggesting that the anti-inflammatory effect of rTMD1 on the inflammatory mediator production is rTMD1-specific.
rTMD1 reduces K. pneumoniae-induced inflammatory responses and lethality, and enhances bacterial clearance
To test whether rTMD1 protects against lethality induced by Gram-negative bacteria, we induced systemic sepsis in mice by injecting i.p. with K. pneumoniae and treating with rTMD1 ( Figure 3A-C) . TNF-α and NO levels were increased within 12 hours in mice receiving K. pneumoniae (5×10 2 CFU). rTMD1 treatment (5−25 mg/kg; i.v.) effectively reduced the TNF-α and NO production ( Figure 3A-B) . For the survival experiment, all mice received K. pneumoniae (5×10 3 CFU) died within 18 hours, whereas 50% of the mice received a single i.v. dose of rTMD1 (10 mg/kg) survived more than 24 hours ( Figure 3C ).
To explore whether the effect of K. pneumoniae-induced mortality results from rTMD1 promoted bacterial clearance, the amount of viable bacteria in the blood was determined.
For For For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From effect as rTMD1 while tagged rTMD23 failed to produce agglutination; similar result was obtained by using mammalian-expressed rTMD1 ( Figure 5A ). The effect of rTMD1 on the phagocytosis of FITC-labeled K. pneumoniae by activated THP-1 cells was assayed. rTMD1 markedly increased the amount of bacterial phagocytosis by THP-1 cells (Figure 5B-C) .
Therefore, rTMD1 not only can interfere with the bacteria-induced inflammatory reaction, but also induce agglutination of bacteria and promote phagocytosis by macrophages.
Identification of ligand specificity of rTMD1 and no competing effect of Le y on
HMGB1-rTMD1 binding
To identify the ligand specificity of TMD1, a panel of carbohydrate ligands ( Figure 6A ) was tested for rTMD1 affinity using the AlphaScreen method. The result showed that Le y antigen was a specific ligand for either mammalian-or Pichia-expressed rTMD1 ( Figure 6A ). Le 23 Therefore, TMD1 provides protection against LPS-induced lethality. However, the direct interaction between TMD1 and LPS has not been demonstrated. we used to induce acute symptom in mice is similar to many previous reports. 20, 32 When LPS is parenterally-administrated to animals, a large proportion of injected LPS is initially found in the cell-free plasma with predominantly binding to plasma proteins including high density lipoproteins and apoproteins. 33, 34 It is expected that only minor amount of injected LPS is available to act on the inflammatory-responded cells. In the in vitro system, we dealt with pure macrophage cell culture which is very sensitive to LPS treatment. LPS concentration used in vitro would be much lower than in vivo system. However, the difficulty of comparing in vitro and in vivo with relative concentrations of TMD1 and LPS still exists since the bioavailability of TMD1 and LPS is dynamic as showed in Figure 2I -J.
In this paper, we used different doses of LPS to perform in vitro and
The family of C-type lectins, through the interaction with carbohydrate recognition domains, participates in innate immune functions such as opsonization, 26, 35 complement activation, 36 and leukocyte-endothelial cell adhesion. 37 In a previous study, we demonstrated that TMD1 is a Ca 2+ -dependent functional lectin involved in cell-cell adhesion. 17 The leukocyte endothelial adhesion molecules E-and P-selectins also consist of N-terminal lectin domains binding to inhibits LPS-increased iNOS expression (Figures 1-2) , and blocks the interaction of CD14
with LPS ( Figure 4D ). Thus, rTMD1 blocks the interaction of LPS with its signaling receptor and then prevents widespread activation of inflammatory reaction in the early stage of sepsis.
To compare the binding selectivity and strength of rTMD1 with other lectin-carbohydrate interactions, we established the approximate affinity for this interaction. From Figure 4B , the 43 implying that the binding of TMD1-LPS/Le y has physiological relevance. rTMD1 not only opsonizes Gram-negative bacteria but also dampens LPS-induced inflammatory reactions. Previous studies reported that increased levels of membrane-shed TM fragments could be detected in circulation and urine, 44 which has been widely accepted as an indicator in various diseases. Two forms of membrane-shed TM fragments (63/57 and 35 kDa) derived from N-terminal extracellular region of TM have been purified from urine. 45 The 63/57 kDa fragment but not the 35 kDa fragment is active for protein C activation, suggesting that the fragment (35 kDa) without protein C activation activity might be membrane-shed TMD1. Many proteases including rhomboids that could mediate TM shedding have been reported. 46 Furthermore, the mechanism of triggering protease-mediated TMD shedding remains unclear. Recent report showed that TM is shed in a metalloproteinases-dependent manner induced by proinflammatory factors. 47 Furthermore, our recent data documented that lysophosphatidic acid induces TMD1 shedding in a metalloproteinases-dependent manner. 29 These results indicated that membrane-shed soluble TMD1 could be generated during inflammatory processes.
Membrane-shed TM fragments that is markedly increased in patients with severe sepsis 48 should not consider merely as a marker of endothelial injury; rather, the TMD1-containing fragments in plasma may represent as one of the natural protective mechanisms to be a decoy receptor and an anti-inflammatory agent especially in Gram-negative bacterial infection.
Membrane-shed TMD1 might not present enough amounts to exert anti-inflammatory function under pathological conditions. Therefore, exogenous administration of rTMD1 may have therapeutic potential. We further evidenced that membrane-bound TMD1could specifically bind LPS ( Figure S4 ). However, the role of membrane-bound TMD1 in LPSinduced inflammatory response remains to be investigated.
For In conclusion, the specific interaction of rTMD1 with Le y highlights a novel mechanism in modulating LPS-mediated inflammatory responses. The therapeutic potential of rTMD1 in treating acute Gram-negative septicemia should be noticed. Moreover, rTMD1 provides an alternative to treat sepsis without the side effect of bleeding that may encounter protein C activating therapy like rTMD23, recombinant TM domains 1, 2, 3, or activated protein C. 21 The identification of Le y as the specific ligand of rTMD1 also paves the way for investigating the roles of TMD1-Le y couple in cell-cell interaction and their biological functions in vivo.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From For personal use at PENN STATE UNIVERSITY on February 21, 2013.
